30
EARLY INTESTINAL ULTRASOUND RESPONSE TO BIOLOGIC AND SMALL MOLECULE THERAPY PREDICTS ENDOSCOPIC OUTCOMES IN CHILDREN WITH ULCERATIVE COLITIS
Date
May 18, 2024
Tracks
Related Products
POINT-OF-CARE INTESTINAL ULTRASOUND ENHANCES DECISION-MAKING IN CROHN’S DISEASE PATIENT VISITS BUT NOT ULCERATIVE COLITIS, AND IS PREFERRED BY PATIENTS FOR DISEASE MONITORING
INTRODUCTION: Point-of-care intestinal ultrasound (IUS) is a non-invasive, accurate inflammatory bowel disease (IBD) monitoring tool. As IUS uptake grows and monitoring strategies become more complex, understanding the impact of IUS on clinical decision-making and monitoring preferences is needed…
IBD Diagnosis. Monitoring, and Prediction of Complications
SOCIETY: AGA This session highlights the latest research on novel prediction models in IBD as well as the role of the fecal microbiome and imaging in IBD…
RISANKIZUMAB VERSUS USTEKINUMAB FOR THE ACHIEVEMENT OF CLINICAL REMISSION AND REDUCTION IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE TRIAL
Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…
PREGNANCY OUTCOMES AFTER MATERNAL OR PATERNAL EXPOSURE IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM
BACKGROUND: Pregnant women with ulcerative colitis (UC) have a higher risk of adverse pregnancy outcomes vs age-matched controls.1 Tofacitinib is an oral Janus kinase inhibitor for the treatment of UC. There are no well-controlled studies on tofacitinib use in pregnant women…